An international ISHLT/ATS/ERS clinical practice guideline: Diagnosis and management of bronchiolitis obliterans syndrome

European Respiratory Journal

Volumn 44, Issue 6, 2014, Pages 1479-1503

  Meyer, Keith C ^a   Raghu, Ganesh ^b   Verleden, Geert M ^c   Corris, Paul A ^d   Aurora, Paul ^e   Wilson, Kevin C ^f   Brozek, Jan ^g   Glanville, Allan R ^h   Egan, Jim J J ⁱ   Arcasoy, Selim ^j   Aris, Robert M ^k   Avery, Robin K ^l   Belperio, John ^m   Behr, Juergen ⁿ   Bhorade, Sangeeta ^o   Boehler, Annette ^p   Chaparro, Cecilia ^q   Christie, Jason D ^r   Dupont, Lieven J ^c   Estenne, Marc ^s   Fisher, Andrew J ^t   Garrity, Edward R ^u   Hadjiliadis, Denis ^r   Hertz, Marshall I ^v   Husain, Shahid ^q   Iversen, Martin ^w   Keshavjee, Shaf ^q   Lama, Vibha N ^x   Levine, Deborah J ^y   Levine, Stephanie M ^r   Lee, James C ^z   Massard, Gilbert ^aa   Mehta, Atul C ^ab   Nathan, Steven D ^l   Orens, Jonathan B ^ac   Palmer, Scott M ^ad   Snell, Greg I ^ae   Stern, Marc ^af   Studer, Sean M ^ag   Sweet, Stuart C ^ah   Tazelaar, Henry D ^ai   Whelan, Timothy P ^aj   Wilkes, David S ^ak   Williams, Trevor J ^al   Zamora, Martin R ^al   more..

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d FREEMAN HOSPITAL   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^g MCMASTER UNIVERSITY   (Canada)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^j Och Spine at New York Presbyterian Hospitals   (United States)

^k UNIVERSITY OF NORTH CAROLINA   (United States)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ RUHR UNIVERSITY BOCHUM   (Germany)

^o NORTHWESTERN UNIVERSITY   (United States)

^p UNIVERSITY OF ZURICH   (Switzerland)

^q UNIVERSITY OF TORONTO   (Canada)

^r UNIVERSITY OF PENNSYLVANIA   (United States)

^s ERASME HOSPITAL   (Belgium)

^t NEWCASTLE UNIVERSITY   (United Kingdom)

^u UNIVERSITY OF CHICAGO   (United States)

^v UNIVERSITY OF MINNESOTA   (United States)

^w Rigshospitalet   (Denmark)

^x UNIVERSITY OF MICHIGAN   (United States)

^y UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^z UNIVERSITÉ DE STRASBOURG   (France)

^aa LERNER RESEARCH INSTITUTE   (United States)

^ab INOVA FAIRFAX HOSPITAL   (United States)

^ac DUKE UNIVERSITY   (United States)

^ad ALFRED HOSPITAL   (Australia)

^ae FOCH HOSPITAL   (France)

^af NEW YORK UNIVERSITY   (United States)

^ag WASHINGTON UNIVERSITY   (United States)

^ah MAYO CLINIC   (United States)

^ai MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^aj INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ak UNIVERSITY OF MELBOURNE   (Australia)

^al UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBODY; AZITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN; DONOR SPECIFIC ANTIBODY; HLA ANTIGEN; METHYLPREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; IMMUNOSUPPRESSIVE AGENT;

ALLERGIC REACTION; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ANTIREFLUX OPERATION; ARTICLE; BRONCHIOLITIS OBLITERANS; CATARACT; CHEMOPROPHYLAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL COMPETENCE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COLITIS; DELAYED GRAFT FUNCTION; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; EVIDENCE BASED MEDICINE; EXTRACORPOREAL PHOTOPHERESIS; FIBEROPTIC BRONCHOSCOPY; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FRAGILITY FRACTURE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEALTH CARE QUALITY; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HISTORY OF MEDICINE; HLA SYSTEM; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERDISCIPLINARY RESEARCH; LOWER RESPIRATORY TRACT INFECTION; LUNG BIOPSY; LUNG GRAFT REJECTION; LUNG LAVAGE; LUNG TRANSPLANTATION; LYMPH NODE IRRADIATION; MEDICAL SOCIETY; NAUSEA; NEPHROTOXICITY; NEUTROPHILIA; NOMENCLATURE; ONSET AGE; OTOTOXICITY; PATIENT SAFETY; PHENOTYPIC PLASTICITY; PHOTOTHERAPY; PRACTICE GUIDELINE; PROGNOSIS; RECOMMENDED DRUG DOSE; RETRANSPLANTATION; RISK FACTOR; RISK REDUCTION; SPIROMETRY; SURGICAL MORTALITY; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MANAGEMENT; GRAFT REJECTION; LUNG; PATHOLOGY; PATHOPHYSIOLOGY; RADIOGRAPHY; REOPERATION;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BIOPSY; BRONCHIOLITIS OBLITERANS; CYCLOSPORINE; DISEASE MANAGEMENT; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; LUNG TRANSPLANTATION; REOPERATION; RISK FACTORS; TACROLIMUS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84916201258     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00107514     Document Type: Article

References (180)

1. Burke CM, Theodore J, Dawkins KD, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplant recipients. Chest 1984; 86: 824-829.
2. Christie JD, Edwards LB, Aurora P, et al. The registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult lung and heart-lung transplantation report -2009. J Heart Lung Transplant 2009; 28: 1031-1049.
3. The International Society for Heart and Lung Transplantation. www.ishlt.org
4. Cooper JD, Billingham M, Egan T, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993; 12: 713-716.
5. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310.
6. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995; 110: 4-13.
7. Reichenspurner H, Girgis RE, Robbins RC, et al. Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg 1996; 62: 1467-1472.
8. Kramer MR, Stoehr C, Whang JL, et al. The diagnosis of obliterative bronchiolitis after heart-lung and lung transplantation: low yield of transbronchial lung biopsy. J Heart Lung Transplant 1993; 12: 675-681.
9. Pomerance A, Madden B, Burke MM, et al. Transbronchial biopsy in heart and lung transplantation: clinicopathologic correlations. J Heart Lung Transplant 1995; 14: 761-773.
10. Chamberlain D, Maurer J, Chaparro C, et al. Evaluation of transbronchial lung biopsy specimens in the diagnosis of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant 1994; 13: 963-971.
11. Burton CM, Iversen M, Carlsen J, et al. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1. J Heart Lung Transplant 2009; 28: 888-893.
12. Schulman LL, Weinberg AD, McGregor C, et al. Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after lung transplantation. Am J Respir Crit Care Med 1998; 157: 1833-1837.
13. Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007; 117: 3498-3506.
14. Belperio JA, Weigt S, Fishbein MC, et al. Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc 2009; 6: 108-121.
15. Weigt SS, Wallace WD, Derhovanessian A, et al. Chronic allograft rejection: epidemiology, diagnosis, pathogenesis, and treatment. Semin Respir Crit Care Med 2010; 31: 189-207.
16. Verleden GM, Vos R, De Vleeschauwer SI, et al. Obliterative bronchiolitis following lung transplantation: from old to new concepts? Transpl Int 2009; 22: 771-779.
17. Schünemann HJ, Jaeschke R, Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006; 174: 605-614.
18. Sato M, Waddell TK, Wagnetz U, et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 2011; 30: 735-742.
19. Lama VN, Murray S, Lonigro RJ, et al. Course of FEV1 after onset of bronchiolitis obliterans syndrome in lung transplant recipients. Am J Respir Crit Care Med 2007; 175: 1192-1198.
20. Woodrow JP, Shlobin OA, Barnett SD, et al. Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant 2010; 29: 1159-1164.
21. Jackson CH, Sharples LD, McNeil K, et al. Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities? J Heart Lung Transplant 2002; 21: 658-666.
22. Brugière O, Pessione F, Thabut G, et al. Bronchiolitis obliterans syndrome after single-lung transplantation: impact of time to onset on functional pattern and survival. Chest 2002; 121: 1883-1889.
23. Burton CM, Carlsen J, Mortensen J, et al. Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2007; 26: 681-686.
24. Nathan SD, Ross DJ, Belman MJ, et al. Bronchiolitis obliterans in single-lung transplant recipients. Chest 1995; 107: 967-972.
25. Vos R, Vanaudenaerde BM, Ottevaere A, et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J Heart Lung Transplant 2010; 29: 1358-1368.
26. Gottlieb J, Szangolies J, Koehnlein T, et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008; 85: 36-41.
27. Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomised controlled trial of azithromycin to prevent bronchiolitis obliterans syndrome after lung transplantation. Eur Respir J 2011; 37: 164-172.
28. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229-1242.
29. Keller CA, Cagle PT, Brown RW, et al. Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation. Chest 1995; 107: 973-980.
30. Girgis RE, Tu I, Berry GJ, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996; 15: 1200-1208.
31. Kroshus TJ, Kshettry VR, Savik K, et al. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997; 114: 195-202.
32. Heng D, Sharples LD, McNeil K, et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998; 17: 1255-1263.
33. Husain AN, Siddiqui MT, Holmes EW, et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999; 159: 829-833.
34. El-Gamel A, Sim E, Hasleton P, et al. Transforming growth factor beta (TGF-b) and obliterative bronchilitis following pulmonary transplantation. J Heart Lung Transplant 1999; 18: 828-837.
35. Sharples LD, McNeil K, Stewart S, et al. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002; 21: 271-281.
36. Burton CM, Iversen M, Scheike T, et al. Is lymphocytic bronchiolitis a marker of acute rejection? An analysis of 2,697 transbronchial biopsies after lung transplantation. J Heart Lung Transplant 2008; 27: 1128-1134.
37. Glanville AR, Aboyoun CL, Havryk A, et al. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med 2008; 177: 1033-1040.
38. Ross DJ, Marchevsky A, Kramer M, et al. ''Refractoriness'' of airflow obstruction associated with isolated lymphocytic bronchiolitis/bronchitis in pulmonary allografts. J Heart Lung Transplant 1997; 16: 832-838.
39. Guilinger RA, Paradis IL, Dauber JH, et al. The importance of bronchoscopy with transbronchial biopsy and bronchoalveolar lavage in the management of lung transplant recipients. Am J Respir Crit Care Med 1995; 152: 2037-2043.
40. Levine SM, Transplant/Immunology Network of the American College of Chest Physicians. A survey of clinical practice of lung transplantation in North America. Chest 2004; 125: 1224-1238.
41. Hopkins PM, Aboyoun CL, Chhajed PN, et al. Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med 2004; 170: 1022-1026.
42. Hachem RR, Khalifah AP, Chakinala MM, et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation 2005; 80: 1406-1413.
43. Khalifah AP, Hachem RR, Chakinala MM, et al. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant 2005; 5: 2022-2030.
44. Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002; 74: 799-804.
45. Lau CL, Palmer SM, Posther KE, et al. Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann Thorac Surg 2000; 69: 1520-1524.
46. Girnita AL, Duquesnoy R, Yousem SA, et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005; 5: 131-138.
47. Sundaresan S, Mohanakumar T, Smith MA, et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 1998; 65: 648-653.
48. Jaramillo A, Smith MA, Phelan D, et al. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999; 67: 1155-1161.
49. Bharat A, Narayanan K, Street T, et al. Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation 2007; 83: 150-158.
50. Bharat A, Kuo E, Steward N, et al. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg 2008; 86: 189-195.
51. Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007; 175: 507-513.
52. Huang HJ, Yusen RD, Meyers BF, et al. Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome. Am J Transplant 2008; 8: 2454-2462.
53. Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008; 85: 771-774.
54. Vos R, Vanaudernaerde BM, De Vleeschauwer SI, et al. De novo or persistent pseudomonal airway colonization after lung transplantation: importance for bronchiolitis obliterans syndrome? Transplantation 2008; 86: 624-625.
55. Gottlieb J, Mattner F, Weissbrodt H, et al. Impact of graft colonization with Gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir Med 2009; 103: 743-749.
56. Keenan RJ, Lega ME, Dummer JS, et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 1991; 51: 433-438.
57. Smith MA, Sundaresan S, Mohanakumar T, et al. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis syndrome. J Thorac Cardiovasc Surg 1998; 116; 812-820.
58. Engelmann I, Welte T, Fühner T, et al. Detection of Epstein-Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation. J Clin Virol 2009; 45: 47-53.
59. Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005; 5: 2031-2036.
60. Bridges ND, Spray TL, Collins MH, et al. Adenovirus infection in the lung results in graft failure after lung transplantation. J Thorac Cardiovasc Surg 1998; 116: 617-623.
61. Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004; 170: 181-187.
62. Billings JL, Hertz MI, Savik K, et al. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant 2002; 21: 559-566.
63. Vilchez RA, Dauber J, McCurry K, et al. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant 2003; 3: 116-120.
64. Palmer SM Jr, Henshaw NG, Howell DN, et al. Community respiratory viral infection in adult lung transplant recipients. Chest 1998; 113: 944-950.
65. D'Ovidio F, Singer LG, Hadjiliadis D, et al. Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung transplant. Ann Thorac Surg 2005; 80: 1254-1260.
66. Blondeau K, Mertens V, Vanaudenaerde BA, et al. Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur Respir J 2008; 31: 707-713.
67. King BJ, Iyer H, Leidi AA, et al. Gastroesophageal reflux in bronchiolitis obliterans syndrome: a new perspective. J Heart Lung Transplant 2009; 28: 870-875.
68. Hadjiliadis D, Duane Davis R, Steele MP, et al. Gastroesophageal reflux disease in lung transplant recipients. Clin Transplant 2003; 17: 363-368.
69. Valentine VG, Gupta MR, Walker JE Jr, et al. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2009; 28: 163-169.
70. Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9: 1903-1911.
71. Weigt SS, Copeland CA, Derhovanessian A, et al. Colonization with small conidia Aspergillus species is associated with bronchiolitis obliterans syndrome: a two-center validation study. Am J Transplant 2013; 13: 919-927.
72. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4: 725-738.
73. Ibrahim L, Dominguez M, Yacoub M. Primary human adult lung epithelial cells in vitro: response to interferon-c and cytomegalovirus. Immunology 1993; 79: 119-124.
74. Geist LJ, Dai LY. Cytomegalovirus modulates interleukin-6 gene expression. Transplantation 1996; 62: 653-658.
75. Vos R, Vanaudenaerde BM, Dupont LJ, et al. Transient airway colonization is associated with airway inflammation after lung transplantation. Am J Transplant 2007; 7: 1278-1287.
76. Bobadilla JL, Jankowska-Gan E, Xu Q, et al. Reflux-induced collagen type v sensitization: potential mediator of bronchiolitis obliterans syndrome. Chest 2010; 138: 363-370.
77. Saini D, Weber J, Ramachandran S, et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant 2011; 30: 624-631.
78. Henke JA, Golden JA, Yelin EH, et al. Persistent increase of BAL neutrophils as a predictor of mortality following lung transplant. Chest 1999; 115: 403-409.
79. Meyer KC, Nunley DR, Dauber JH, et al. Neutrophils, unopposed neutrophil elastase, and a1-antiprotease defenses following human lung transplantation. Am J Respir Crit Care Med 2001; 164: 97-102.
80. Reynaud-Gaubert M, Marin V, Thirion X, et al. Upregulation of chemokines in bronchoalveolar lavage fluid as a predictive marker of post-transplant airway obliteration. J Heart Lung Transplant 2002; 21: 721-730.
81. DiGiovine B, Lynch JP 3rd, Martinez FJ, et al. Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. J Immunol 1996; 157: 4194-4202.
82. Neurohr C, Huppmann P, Leuchte H, et al. Human herpesvirus 6 in bronchoalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am J Transplant 2005; 5: 2982-2991.
83. Schloma J, Slebos DJ, Boezen HM, et al. Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med 2000; 162: 2221-2225.
84. Lama VN, Murray S, Mumford JA, et al. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in singlelung transplant recipients. Am J Respir Crit Care Med 2005; 172: 379-383.
85. Hachem RR, Chakinala MM, Yusen RD, et al. The predictive value of bronchiolitis obliterans syndrome stage 0-p. Am J Respir Crit Care Med 2004; 169: 468-472.
86. Nathan SD, Barnett SD, Wohlrab J, et al. Bronchiolitis obliterans syndrome: utility of the new guidelines in single lung transplant recipients. J Heart Lung Transplant 2003; 22: 427-432.
87. Morrish WF, Herman SJ, Weisbrod GL, et al. Bronchiolitis obliterans after lung transplantation: findings at chest radiography and high resolution CT. The Toronto Lung Transplant Group. Radiology 1991; 179: 487-490.
88. Kundu S, Herman SJ, Larhs A, et al. Correlation of chest radiographic findings with biopsy-proven acute lung rejection. J Thorac Imaging 1999; 14: 178-184.
89. Collins J. Imaging of the chest after lung transplantation. J Thorac Imaging 2002; 17: 102-112.
90. Leung AN, Fisher K, Valentine V, et al. Bronchiolitis obliterans after lung transplantation: detection using expiratory HRCT. Chest 1998; 113: 365-370.
91. Bankier AA, Van Muylem A, Knoop C, et al. Bronchiolitis obliterans syndrome in heart-lung transplant recipients: diagnosis with expiratory CT. Radiology 2001; 218: 533-539.
92. Lee ES, Gotway MB, Reddy GP, et al. Early bronchiolitis obliterans following lung transplantation: accuracy of expiratory thin-section CT for diagnosis. Radiology 2000; 216: 472-477.
93. Berstad AE, Aaløkken TM, Kolbenstvedt A, et al. Performance of long-term CT monitoring in diagnosing bronchiolitis obliterans after lung transplantation. Eur J Radiol 2006; 58: 124-131.
94. Konen E, Gutierrez C, Chaparro C, et al. Bronchiolitis obliterans syndrome in lung transplant recipients: can thinsection CT findings predict disease before its clinical appearance? Radiology 2004; 231: 467-473.
95. Tepper RS, Reister T. Forced expiratory flows and lung volumes in normal infants. Pediatr Pulmonol 1993; 15: 357-361.
96. Castile R, Filbrun D, Flucke R, et al. Adult-type pulmonary function tests in infants without respiratory disease. Pediatr Pulmonol 2000; 30: 215-227.
97. Siegel MJ, Bhalla S, Gutierrez FR, et al. Post-lung transplantation bronchiolitis obliterans syndrome: usefulness of expiratory thin-section CT for diagnosis. Radiology 2001; 220: 455-462.
98. Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002; 61: 718-722.
99. Ross DJ, Lewis MI, Kramer M, et al. FK 506 ''rescue'' immunosuppression for obliterative bronchiolitis after lung transplantation. Chest 1997; 112: 1175-1179.
100. Borro JM, Bravo C, Solé A, et al. Conversion from cyclosporine to tacrolimus stabilizes the course of lung function in lung transplant recipients with bronchiolitis obliterans syndrome. Transplant Proc 2007; 39: 2416-2419.
101. Knoop C, Antoine M, Vachiéry JL, et al. FK 506 rescue therapy for irreversible airway rejection in heart-lung transplant recipients: report on five cases. Transplant Proc 1994; 26: 3240-3241.
102. Reichenspurner H, Meiser BM, Kur F, et al. First experience with FK 506 for treatment of chronic pulmonary rejection. Transplant Proc 1995; 27: 2009.
103. Kesten S, Chaparro C, Scavuzzo M, et al. Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome. J Heart Lung Transplant 1997; 16: 905-912.
104. Mentzer RM Jr, Jahania MS, Lasley RD. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. Transplantation 1998; 65: 109-113.
105. Revell MP, Lewis ME, Llewellyn-Jones CG, et al. Conservation of small-airway function by tacrolimus/cyclosporine conversion in the management of bronchiolitis obliterans following lung transplantation. J Heart Lung Transplant 2000; 19: 1219-1223.
106. Fieguth HG, Krueger S, Wiedenmann DE, et al. Tacrolimus for treatment of bronchiolitis obliterans syndrome after unilateral and bilateral lung transplantation. Transplant Proc 2002; 34: 1884.
107. Cairn J, Yek T, Banner NR, et al. Time-related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2003; 22: 50-57.
108. Sarahrudi K, Estenne M, Corris P, et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 2004; 127: 1126-1132.
109. Webster A, Woodroffe RC, Taylor RS, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005; 4: CD003961.
110. Gerhardt SG, McDyer JF, Girgis RE, et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003; 168: 121-125.
111. Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004; 77: 1465-1467.
112. Yates B, Murphy DM, Forrest IA, et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005; 172: 772-775.
113. Shitrit D, Bendayan D, Gidon S, et al. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 2005; 24: 1440-1443.
114. Verleden GM, Vanaudenaerde BM, Dupont LJ, et al. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006; 174: 566-570.
115. Porhownik NR, Batobara W, Kepron W, et al. Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplant patients. Can Respir J 2008; 15: 199-202.
116. Jain R, Hachem RR, Morrell MR, et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 2010; 29: 531-537.
117. Panpanich R, Lerttrakarnnon P, Laopaiboon M. Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst Rev 2008; 1: CD001954.
118. Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013; 368: 1704-1712.
119. US Food and Drug Administration. FDA Drug Safety Communication: Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. www.fda.gov/drugs/drugsafety/ucm341822.htm Date last accessed: September 11, 2013. Date last updated: March 18, 2013.
120. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-698.
121. Young LR, Hadjiliadis D, Davis RD, et al. Lung transplantation exacerbates gastroesophageal reflux disease. Chest 2003; 124: 1689-1693.
122. Sweet MP, Patti MG, Leard LE, et al. Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J Thorac Cardiovasc Surg 2007; 133: 1078-1084.
123. Linden PA, Gilbert RJ, Yeap BY, et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg 2006; 131: 438-446.
124. Gasper WJ, Sweet MP, Hoopes C, et al. Antireflux surgery for patients with end-stage lung disease before and after lung transplantation. Surg Endosc 2008; 22: 495-500.
125. Benden C, Aurora P, Curry J, et al. High prevalence of gastroesophageal reflux disease in lung transplant recipients. Pediatr Pulmonol 2005; 40: 68-71.
126. O'Halloran EK, Reynolds JD, Lau CL, et al. Laparoscopic Nissen fundoplication for treating reflux in lung transplant recipients. J Gastrointest Surg 2004; 8: 132-137.
127. Davis RD Jr, Lau CL, Eubanks S, et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 2003; 125: 533-542.
128. Cantu E 3rd, Appel JZ 3rd, Hartwig MG, et al. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 2004; 78: 1142-1151.
129. Davis CS, Gagermeier J, Dilling D, et al. A review of the potential applications and controversies of non-invasive testing for biomarkers of aspiration in the lung transplant population. Clin Transplant 2010; 24: E54-E61.
130. D'Ovidio F, Mura M, Tsang M, et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg 2005; 129: 1144-1152.
131. Hopkins PM, Kermeen F, Duhig E, et al. Oil red O stain of alveolar macrophages is an effective screening test for gastroesophageal reflux disease in lung transplant recipients. J Heart Lung Transplant 2010; 29: 859-864.
132. Lau CL, Palmer SM, Howell DN, et al. Laparoscopic antireflux surgery in the lung transplant population. Surg Endosc 2002; 16: 1674-1678.
133. Zheng C, Kane TD, Kurland G, et al. Feasibility of laparoscopic Nissen fundoplication after pediatric lung or heartlung transplantation: should this be the standard? Surg Endosc 2011; 25: 249-254.
134. Burton PR, Button B, Brown W, et al. Medium-term outcome of fundoplication after lung transplantation. Dis Esophagus 2009; 22: 642-648.
135. Fisichella PM, Davis CS, Gagermeier J, et al. Laparoscopic antireflux surgery for gastroesophageal reflux disease after lung transplantation. J Surg Res 2011; 170: e279-e286.
136. Hartwig MG, Anderson DJ, Onaitis MW, et al. Fundoplication after lung transplantation prevents the allograft dysfunction associated with reflux. Ann Thorac Surg 2011; 92: 462-468.
137. Hoppo T, Jarido V, Pennathur A, et al. Antireflux surgery preserves lung function in patients with gastroesophageal reflux disease and end-stage lung disease before and after lung transplantation. Arch Surg 2011; 146: 1041-1047.
138. Fisichella PM, Davis CS, Lundberg PW, et al. The protective role of laparoscopic antireflux surgery against aspiration of pepsin after lung transplantation. Surgery 2011; 150: 598-606.
139. Wang Z, Zheng Q, Jin Z. Meta-analysis of robot-assisted versus conventional laparoscopic Nissen fundoplication for gastro-oesophageal reflux disease. ANZ J Surg 2012; 82: 112-117.
140. Khatri K, Sajid MS, Brodrick R, et al. Laparoscopic Nissen fundoplication with or without short gastric vessel division: a meta-analysis. Surg Endosc 2012; 26: 970-978.
141. Brugière O, Thabut G, Castier Y, et al. Lung retransplantation for bronchiolitis obliterans syndrome: long-term follow-up in a series of 15 recipients. Chest 2003; 123: 1832-1837.
142. Strueber M, Fischer S, Gottlieb J, et al. Long-term outcome after pulmonary retransplantation. J Thorac Cardiovasc Surg 2006; 132: 407-412.
143. Aigner C, Jaksch P, Taghavi S, et al. Pulmonary retransplantation: is it worth the effort? A long-term analysis of 46 cases. J Heart Lung Transplant 2008; 27: 60-65.
144. Osaki S, Maloney JD, Meyer KC, et al. Redo lung transplantation for acute and chronic lung allograft failure: longterm follow-up in a single center. Eur J Cardiothorac Surg 2008; 34: 1191-1197.
145. Novick RJ, Stitt L, Schäfers HJ, et al. Pulmonary retransplantation: does the indication for operation influence postoperative lung function? J Thorac Cardiovasc Surg 1996; 112: 1504-1513.
146. Novick RJ, Stitt LW, Al-Kattan K, et al. Pulmonary retransplantation: predictors of graft function and survival in 230 patients. Pulmonary Retransplant Registry. Ann Thorac Surg 1998; 65: 227-234.
147. Kawut SM, Lederer DJ, Keshavjee S, et al. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med 2008; 177: 114-120.
148. Keshavjee S. Retransplantation of the lung comes of age. J Thorac Cardiovasc Surg 2006; 132: 226-228.
149. Sato M, Ohmori-Matsuda K, Saito T, et al. Time-dependent changes in the risk of death in pure bronchiolitis obliterans syndrome (BOS). J Heart Lung Transplant 2013; 32: 484-491.
150. Vanaudenaerde BM, De Vleeschauwer SI, Vos R, et al. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2008; 8: 1911-1920.
151. Serody JS, Hill GR. The IL-17 differentiation pathway and its role in transplant outcome. Biol Blood Marrow Transplant 2012; 18: S56-S61.
152. Shilling RA, Wilkes DS. Role of Th17 cells and IL-17 in lung transplant rejection. Semin Immunopathol 2011; 33: 129-134.
153. Vanaudenaerde BM, Verleden SE, Vos R, et al. Innate and adaptive interleukin-17-producing lymphocytes in chronic inflammatory lung disorders. Am J Respir Crit Care Med 2011; 183: 977-986.
154. Afzali B, Lombardi G, Lechler RI, et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148: 32-46.
155. Fan L, Benson HL, Vittal R, et al. Neutralizing IL-17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation. Am J Transplant 2011; 11: 911-922.
156. Vittal R, Fan L, Greenspan DS, et al. IL-17 induces type V collagen overexpression and EMT via TGF-b dependent pathways in obliterative bronchiolitis. Am J Physiol Lung Cell Mol Physiol 2013; 304: L401-L414.
157. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
158. Neujahr DC, Larsen CP. Regulatory T cells in lung transplantation -an emerging concept. Semin Immunopathol 2011; 33: 117-127.
159. Tiriveedhi V, Takenaka M, Ramachandran S, et al. T regulatory cells play a significant role in modulating MHC class I antibody-induced obliterative airway disease. Am J Transplant 2012; 12: 2663-2674.
160. Shi Q, Cao H, Liu J, et al. CD4+ Foxp3+ regulatory T cells induced by TGF-b, IL-2 and all-trans retinoic acid attenuate obliterative bronchiolitis in rat trachea transplantation. Int Immunopharmacol 2011; 11: 1887-1894.
161. Braun RK, Molitor-Dart M, Wigfield C, et al. Transfer of tolerance to collagen type V suppresses T-helper-cell-17 lymphocyte-mediated acute lung transplant rejection. Transplantation 2009; 88: 1341-1348.
162. Griffin DO, Rothstein TL. Human ''orchestrator'' CD11b+ B1 cells spontaneously secrete interleukin-10 and regulate T-cell activity. Mol Med 2012; 18: 1003-1008.
163. Li W, Bribriesco AC, Nava RG, et al. Lung transplant acceptance is facilitated by early events in the graft and is associated with lymphoid neogenesis. Mucosal Immunol 2012; 5: 544-554.
164. Ward C, Forrest IA, Murphy DM, et al. Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients. Thorax 2005; 60: 865-871.
165. Hodge S, Holmes M, Banerjee B, et al. Posttransplant bronchiolitis obliterans syndrome is associated with bronchial epithelial to mesenchymal transition. Am J Transplant 2009; 9: 727-733.
166. Borthwick LA, Parker SM, Brougham KA, et al. Epithelial to mesenchymal transition (EMT) and airway remodelling after human lung transplantation. Thorax 2009; 64: 770-777.
167. Gardner A, Fisher AJ, Richter C, et al. The critical role of TAK1 in accentuated epithelial to mesenchymal transition in obliterative bronchiolitis after lung transplantation. Am J Pathol 2012; 180: 2293-2308.
168. Cypel M, Yeung JC, Hirayama S, et al. Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant 2008; 27: 1319-1325.
169. Cypel M, Rubacha M, Yeung J, et al. Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation. Am J Transplant 2009; 9: 2262-2269.
170. Ingemansson R, Eyjolfsson A, Mared L, et al. Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo. Ann Thorac Surg 2009; 87: 255-260.
171. Aigner C, Slama A, Hötzenecker K, et al. Clinical ex vivo lung perfusion -pushing the limits. Am J Transplant 2012; 12: 1839-1847.
172. Zych B, Popov AF, Stavri G, et al. Early outcomes of bilateral sequential single lung transplantation after ex-vivo lung evaluation and reconditioning. J Heart Lung Transplant 2012; 31: 274-281.
173. Fisher AJ, Rutherford RM, Bozzino J, et al. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2005; 5: 537-543.
174. Diamond DA, Michalski JM, Lynch JP, et al. Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation. Int J Radiat Oncol Biol Phys 1998; 41: 795-800.
175. Benden C, Speich R, Hofbauer GF, et al. Extracorporeal photopheresis after lung transplantation: a 10-year singlecenter experience. Transplantation 2008; 86: 1625-1627.
176. Morrell MR, Despotis GJ, Lublin DM, et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2010; 29: 424-431.
177. Cahill BC, Somerville KT, Crompton JA, et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant 2003; 22: 169-176.
178. Reams BD, Musselwhite LW, Zaas DW, et al. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant 2007; 7: 2802-2808.
179. Shyu S, Dew MA, Pilewski JM, et al. Five-year outcomes with alemtuzumab induction after lung transplantation. J Heart Lung Transplant 2011; 30: 743-754.
180. Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation 2010; 90: 1511-1515.